Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
BARCELONA, Spain and NEW YORK , March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B
View HTML
Toggle Summary Assembly Biosciences to Webcast Upcoming Investor Conferences
INDIANAPOLIS , Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection,
View HTML
Toggle Summary Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel® Technology Achieves Targeted Delivery to the Lower GI Tract
Phase I Scintigraphy Data Confirms Gemicel Can Deliver Therapeutics to Targeted Regions of the Lower GI Tract Favorable for Microbiome Therapies
View HTML
Toggle Summary Assembly Biosciences Expands Senior Leadership Team
INDIANAPOLIS , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level hires across the
View HTML
Toggle Summary Assembly Biosciences Appoints Biotech Veteran Alan J. Lewis to Board of Directors
INDIANAPOLIS , Dec. 21, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced the appointment of Alan J.
View HTML
Toggle Summary Assembly Biosciences to Present at Jefferies Microbiome Summit
INDIANAPOLIS , Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the company will participate in the Jefferies
View HTML
Toggle Summary Clinical Study Shows Assembly Biosciences' Oral Gemicel® Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications
—Assembly is Developing Curative Treatments for HBV, Resistant C. difficile Infections (CDI) and Other Infectious Diseases— —Expects to Initiate Phase lb Trial in 2016 Using Gemicel to Deliver Selected Bacteria Strains to the GI Tract that Recapitulate the Effects of FMT as Treatment for CDI— NEW
View HTML
Toggle Summary Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
— Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B  Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— — Assembly Also Reporting New Peer-Reviewed Publication Highlighting Key Role of HBV Core Protein—             NEW YORK and
View HTML
Toggle Summary Assembly Biosciences Discusses Mechanism of Action of Its HBV Antiviral Program at 2nd ANRS HBV Cure Workshop
Workshop Sponsored by French National Agency for Research on AIDS and Viral Hepatitis
View HTML
Toggle Summary Assembly Biosciences Announces Pricing of $75 Million Public Offering of Its Common Stock
NEW YORK , March 19, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly") announced today the pricing of an underwritten public offering of $75 million , or 5,555,555 shares of its common stock pursuant to an effective shelf registration statement that was previously filed
View HTML